Exhibit 99.1 Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 1, 2024 (GLOBE NEWSWIRE) –Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for ...

Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Barry Shin - Senior Vice President, Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Senior Vice President, Chief Medical Officer Daniel Clauw - Key Opinion Leader and Paid Scientific Consultant Conference Call Participants Jason Butler - JMP Securities Douglas Tsao - H.C. Wainwright Operator Greetings and welcome to Trevena, Inc. Third Quarter 2023 Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdictio ...

Trevena, Inc. (NASDAQ:TRVN) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Operator Hello and welcome to Trevena, Inc. First Quarter 2023 Earnings Call. All participants will be in listen only mode. [Operator Instruc ...

Existing S1PR-targeted drugs, however, are ill-suited for CNS indications due to known: Lymphopenia Pulmonary AEs Cardiac AEs Ophthalmologic AEs 1) Sim-Selley et al., Journal of Pharmacology & Experimental Therapeutics, 2018. 2) Sim-Selley et al, Journal of Neurochemistry, 2008. 3) Gol et al., European Journal of Pharmaceutical Sciences, 2017. 4) Leo et al, CNS & Neurological Disorders - Drug Targets, 2017. 5) Choi, et al. PNAS 2011. 25 TRV045: Novel MOA, Selective S1PR % non-responseto pain stimulus Revers ...

Table of Contents For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware (State or Other Jurisdicti ...

Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call. [Operator I ...

Financial Performance - Total revenue for the year ended December 31, 2022, was $(418) thousand, a decrease from $567 thousand in 2021, representing a decline of approximately 173.7%[546] - Operating expenses increased to $55,957 thousand in 2022 from $52,492 thousand in 2021, marking an increase of about 9.4%[546] - The net loss for 2022 was $(53,670) thousand, compared to a net loss of $(51,588) thousand in 2021, reflecting an increase in loss of approximately 4.0%[546] - The company reported a comprehensive loss of $(53,669) thousand for 2022, compared to $(51,588) thousand in 2021, indicating a worsening of approximately 4.0%[546] - The company recognized a net loss of $53,670,000 for the year ended December 31, 2022, compared to a net loss of $51,588,000 in 2021, resulting in a net loss per share of $(7.59) for 2022[676] Cash and Liquidity - Cash and cash equivalents decreased to $38,320 thousand as of December 31, 2022, down from $66,923 thousand in 2021, a decline of about 42.5%[543] - The Company’s cash and cash equivalents totaled $40,280,000 as of December 31, 2022, compared to $68,234,000 in 2021, indicating a significant decrease in liquidity[597] - The company had a cash decrease of $(27,954) thousand for the year, compared to a decrease of $(42,479) thousand in 2021, showing an improvement of approximately 34.3%[551] Assets and Liabilities - Total assets decreased to $48,680 thousand in 2022 from $80,124 thousand in 2021, a reduction of approximately 39.2%[543] - Total liabilities increased significantly to $33,081 thousand in 2022 from $15,495 thousand in 2021, an increase of about 113.5%[543] - The Company has incurred an accumulated deficit of $547.8 million as of December 31, 2022, with a net loss of $53.7 million for the year ended December 31, 2022[556] Funding and Capital Structure - The company recorded gross proceeds of $15 million from a loan agreement with R-Bridge Healthcare Investment Advisory, Ltd. in April 2022[539] - Management's plans include securing additional funding to support future operating expenses and capital expenditures[9] - The Company has entered into a Loan Agreement allowing for up to $40 million in term loan borrowings, with the first tranche of $15 million already advanced in April 2022[611] - The Company was in compliance with all covenants of the Loan Agreement as of December 31, 2022, with no events of default reported[615] Research and Development - The Company capitalized approximately $18.7 million of research and development (R&D) expenses as of December 31, 2022, due to the Tax Cuts and Jobs Act of 2017 requiring capitalization of R&D costs[682] - Research and development costs are charged to expense as incurred, including personnel expenses and clinical trial costs[577] - The Company capitalized $80.648 million in research and development expenses for tax purposes as of December 31, 2022, down from $93.254 million in 2021[680] Stock and Compensation - The Company has two stock-based compensation plans and recognizes compensation expense based on estimated grant-date fair values[583] - Total stock-based compensation expense recognized for the year ended December 31, 2022, was $3.676 million, a decrease from $4.407 million in 2021[636] - The Company granted 39,998 stock options in 2022 at a weighted average exercise price of $11.47, compared to 149,905 options granted in 2021 at $39.91[637] - The estimated grant-date fair value of options granted in 2022 was $8.88 per share, down from $31.19 per share in 2021[639] Tax and Deferred Tax - The Company has a full valuation allowance against its deferred tax assets, which decreased by $7,500,000 for the year ended December 31, 2022[679] - Total deferred tax assets as of December 31, 2022, amounted to $147.781 million, a decrease from $155.259 million in 2021[680] - The Company has federal research and development tax credit carryforwards of $16.3 million that begin to expire in 2027[681] Market and Competition - The company is assessing the potential market acceptance of its product candidates in light of existing competition[9] - The company is focused on successfully commercializing OLINVYK and other product candidates pending regulatory approval[9] - Future commercialization activities will include product manufacturing, marketing, sales, and distribution for approved product candidates[523]

Trevena, Inc. (OTC:TRVN) Q3 2022 Results Earnings Conference Call November 13, 2022 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Douglas Tsao - H.C. Wainwright & Co. Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Jeff Jones - Oppenheimer & Co. Inc. Operator Greetings and welcome to Trevena Inc. Third Quarte ...